Medtronic plcMDT commercially launched MiniMed 670G system, a Hybrid Closed Loop insulin delivery system for Type I diabetic patients. This happened following the U.S. FDA approval late last year.
When Medtronic won approval for the MiniMed 670G from the FDA in 2016, it was a big deal. Advertised as “The World’s First Hybrid Closed Loop System,” it is the first commercial product of its kind – ...
Roughly 1.25 million Americans have Type 1 diabetes, so chances are you know somebody whose pancreas is taking the world’s longest lunch break. That person may be you. As it happens, there has never ...
Results show how the hybrid closed loop system reduced glycemic variability, which leads to fewer long-term complications from type 1 disease. The trial reports what had been announced already: the ...
Medtronic touted new clinical data from its growing base of MiniMed 670G insulin-pump users, noting on Tuesday that people who used the pump's most advanced features kept their blood sugar levels ...
Sales of the company’s MiniMed 670G device, which is the med-tech giant's latest “artificial pancreas” system, partly drove the diabetes division's strong performance. Medtronic reported earnings that ...
The FDA announced that Medtronic expanded two recalls relating to the MiniMed 600 series of insulin pumps and MiniMed 508 remote controllers. Both were designated by the agency as Class I, the most ...
Medtronic plc. MDT recently announced that its MiniMed 670G insulin pump system secured German reimbursement. This achievement marks a major regulatory breakthrough for the company. The German Federal ...
Value-based care and paying for performance are not the order of the day yet, but incremental moves are being made to move away from a fee-for-service world. The latest evidence of it comes from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback